Nephrogenic systemic fibrosis: A sufficient reason to avoid gadolinium-based contrast in all patients with renal impairment?

Seminars in Dialysis

Volumn 21, Issue 2, 2008, Pages 140-141

  Willicombe, Michelle ^a   Cunningham, John ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ARTICLE; CHEMISTRY; DRUG CONTRAINDICATION; FIBROSIS; HUMAN; KIDNEY FAILURE; METABOLISM; PATHOLOGY; RISK FACTOR;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 40849130966     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00400.x     Document Type: Article

References (15)

1. The International Center for Nephrogenic Fibrosing Dermopathy Research. Available at: http://www.icndr.org (Accessed August 3, 2007)
2. Food an Drug Administration Public Health Advisory. Available at: http://www.fda.gov/cder/drug/advisory/GBC_agents.htm (Accessed August 3, 2007)
3. Medicines and Health products Regulatory Agency. Available at: http://www.mhra.gov.uk (Accessed August 3, 2007)
4. Gibson SE, Farver CF, Prayson RA : Multiorgan involvement in nephrogenic fibrosing nephropathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130 : 209 212, 2006
5. Kucher C, Steere J, Elenitsas R, Siegel D, Xu X : Nephrogenic fibrosing nephropathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 54 : S31 S34, 2006
6. Todd DJ. Nephrogenic systemic fibrosis: what nephrologists need to know. Nephrol Rounds 5 : 1 6, 2007
7. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA : Description of 12 cases of nephrogenic fibrosing dermapothy and review of the literature. Semin Arthritis Rheum 35 : 238 249, 2006
8. Maloo M, Abt P, Kashyap R, Younan D, Zand M, Orloff M : Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 6 : 2212 2217, 2006
9. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA : Gadodiamide associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roetgenol 188 : 586 592, 2007
10. Swaminathan S, Shah S : New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18 : 2636 2643, 2007
11. Morcos SK : Nephrogenic systemic fibrosis following the administration of extracellular GBC based contrast agents: is the stability of the contrast molecule an important factor in the pathogenesis of this condition? Br J Radiol 80 : 73 76, 2007
12. Aneet D, Mitchell F, Cowper S : Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to GBC exposure. Clin J Am Soc Nephrol 2 : 264 267, 2007
13. Centre of Disease Control and Prevention. Nephrogenic Fibrosing Dermopathy Associated With Exposure to GBC-Containing Contrast Agents - St. Louis, Missouri : 2002-2006. MMWR 2007 56 : 1
14. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y : Dialysability of gadodiamide in haemodialysis patients. Radiat Med 24 : 445 451, 2006
15. Pannu N, Wiebe N, Tonelli M : Prophylaxis strategies for contrast induced nephropathy. JAMA 295 : 2765 2779, 2006